News coverage about Pacira Pharmaceuticals (NASDAQ:PCRX) has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.3937664512597 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up $3.05 on Friday, reaching $36.10. 1,280,000 shares of the company’s stock traded hands, compared to its average volume of 700,269. The company has a debt-to-equity ratio of 1.03, a current ratio of 7.84 and a quick ratio of 7.26. Pacira Pharmaceuticals has a 1-year low of $29.81 and a 1-year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business had revenue of $70.90 million during the quarter, compared to analyst estimates of $73.37 million. During the same period in the previous year, the business posted $0.21 earnings per share. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. sell-side analysts anticipate that Pacira Pharmaceuticals will post -0.96 earnings per share for the current fiscal year.

A number of research firms recently commented on PCRX. Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Wednesday, August 2nd. Piper Jaffray Companies reiterated a “buy” rating and set a $55.00 price target on shares of Pacira Pharmaceuticals in a report on Friday, October 27th. Mizuho reiterated a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. Goldman Sachs Group, Inc. (The) began coverage on Pacira Pharmaceuticals in a report on Thursday, September 28th. They set a “neutral” rating and a $41.00 price target for the company. Finally, BidaskClub cut Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $50.43.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Pacira Pharmaceuticals (PCRX) Share Price” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at

In other Pacira Pharmaceuticals news, CEO David M. Stack sold 28,885 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total value of $1,050,547.45. Following the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at approximately $5,788,794.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Paul J. Hastings sold 1,044 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total value of $37,740.60. Following the completion of the sale, the director now directly owns 3,518 shares in the company, valued at $127,175.70. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,390 shares of company stock worth $1,215,480. 6.60% of the stock is owned by corporate insiders.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.